Financials
- Financial year
- 2025
- Total assets
- €3.9m
- Loss
- -€832,803
- Solvency
- 16.5%
Total assets▲ 6.6%
Net result
20182025
NOVOBIOM
ActiveSummary
The annual accounts of NOVOBIOM for financial year 2025 show a net loss of 105% of the equity at the start of that year. The 2025 annual accounts show equity of €645,292 and a net result of -€832,803. Equity is growing by about 22% per year across the filed financial years. Its solvency ranks better than 32% of 268 sector peers (NACE 72, financial year 2025). The company has been active since 2017 and the Belgian Official Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 0.1% (very low).
Overview
Activity
Research and development on biotechnology
NACE 72101
1 site
Size
€3.9mtotal assets 2025
- Staff
- 11.6 FTE
- Equity
- €645,292
- Loss
- -€832,803
Turnover not published (abbreviated or micro format)Net result -149%: other schema
Structure
- Largest shareholder
- NOSHAQ · 11.43%
Accounts 7 days early0 of 5 deeds read
Why 54raises riskCapped at 59: a net loss of at least half of total assets or of the equity at the start of the financial yearLoss of €832,803, the second in a row (financial year 2025)lowers riskSize: total assets €3.9mFigures for financial year 2025 (filed 24-07-2026)Sector: Scientific research and development (NACE 72)Show the evidence
Checked score
Score 2025
54
/ 100
Fair
Probability in this band: 1.5% to 4.2%
Financially better than 30% of its sector peers (NACE 72, small)
A net loss of at least half of total assets or of the equity at the start of the financial year caps the score at 59. Every signal that counts is listed under Signals.
Financial strength · tick = 2024
Weak
Solvency
41-6
equity 16.5% of total assets
Liquidity
63-26
short-term debt 27.7% · cash 19.5%
Profitability
0-28
return on assets -21.3%
Bankruptcy probability, 12 months
0.1%
Very low
0%0.5%1.5%4%10%≥ 25%
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
11-2024: 0.1%
12-2024: 0.1%● unchanged vs 11-2024
01-2025: 0.1%● unchanged vs 12-2024
02-2025: 0.1%● unchanged vs 01-2025
03-2025: 0.1%● unchanged vs 02-2025
04-2025: 0.1%● unchanged vs 03-2025
05-2025: 0.1%● unchanged vs 04-2025
06-2025: 0.1%● unchanged vs 05-2025
07-2025: 0.1%● unchanged vs 06-2025
08-2025: 0.3%▲ +0.2 percentage points vs 07-2025highest value
09-2025: < 0.1%▼ -0.3 percentage points vs 08-2025lowest value
10-2025: < 0.1%● unchanged vs 09-2025lowest value
11-2025: < 0.1%● unchanged vs 10-2025lowest value
12-2025: < 0.1%● unchanged vs 11-2025lowest value
01-2026: < 0.1%● unchanged vs 12-2025lowest value
02-2026: < 0.1%● unchanged vs 01-2026lowest value
03-2026: < 0.1%● unchanged vs 02-2026
04-2026: 0.1%▲ +0.1 percentage points vs 03-2026
05-2026: 0.1%● unchanged vs 04-2026
06-2026: 0.1%● unchanged vs 05-2026
07-2026: 0.1%● unchanged vs 06-2026
08-2026: 0.1%● unchanged vs 07-2026
09-2026: 0.1%● unchanged vs 08-2026
10-2026: 0.1%● unchanged vs 09-2026
Credit of up to €30,000 on 30-day terms, only on tighter conditions
Net loss of at least half of total assets or of the equity at the start of the financial year.
Liquidity ample (current ratio 1.55, compared with 2.81 in 2024, above the usual 1.5; short-term debt: 27.7% and cash: 19.5% of total assets), but 83.5% of the assets are financed with debt and provisions.
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, small): better than 23% on solvency, 64% on liquidity, 11% on profitability and 21% on growth.
The bankruptcy probability was computed on 12-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Persistent losses
Two consecutive loss-making years (2024 and 2025); equity is also lower. May indicate structural pressure on profitability.
NBB · annual accounts 2025Net result per financial year
1819202122232425
2018 to 2025 · latest year -€832,803
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 24-07-2026, 7 days ahead of the deadline.
NBB · 9 filingsDeviation from the deadline
2025
7 days early
2024
29 days late
2023
8 days early
2022
7 days early
2021
37 days early
2020
40 days early
2019
46 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 17 days before the deadline; the sector median (NACE 72) for financial year 2024 is 13 days before the deadline, and 33% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 24 July (4 of the last 5 filed years within 30 days of that day).
Companies Code · seven monthsWhere today falls in the filing period
13-10-2026 today31-12-2026 year end31-07-2027 deadline
- Annual accounts filedfinancial year 2025 · abbreviated…
- Weakest financial yearnet -€832,803
- Annual accounts filedfinancial year 2024 · micro…
Key points
By topic
Board & ownership
- Largest shareholder
- NOSHAQ · 11.43%
Timeline
- Events
- 15
- Since
- 2018
- Next accounts
- by 31-07-2027
- 31-12-2024Liquidity more than doubled
- 23-07-2024Annual accounts filed
- 24-07-2023Annual accounts filed
Company details
- Sites
- 1
- Legal form
- Public limited company
- Activity
- Research and development on biotechnologyNACE 72101
- Founded
- 24-02-2017
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Go further with this company
How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What support did similar companies receive that this one did not?Subsidies How does this company compare with its sector?Sector benchmark
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.